MedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryCannabis
SectorMedical
SymbolTSE:LEAF
CUSIPN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-21.65%
Return on Equity-6.38%
Return on Assets-5.47%
Miscellaneous
EmployeesN/A
Outstanding Shares99,145,000
MedReleaf (TSE:LEAF) Frequently Asked Questions
What is MedReleaf's stock symbol?
MedReleaf trades on the Toronto Stock Exchange (TSX) under the ticker symbol "LEAF."
What price target have analysts set for LEAF?
2 brokers have issued 1-year price targets for MedReleaf's shares. Their predictions range from C$20.00 to C$36.00. On average, they anticipate MedReleaf's share price to reach C$28.75 in the next year. View Analyst Ratings for MedReleaf.
Who are some of MedReleaf's key competitors?
Some companies that are related to MedReleaf include Canopy Growth (WEED), Aurora Cannabis (ACB), STADA Arzneimittel (SAZ), Hikma Pharmaceuticals (HKMPY), Hikma Pharmaceuticals (HIK), Aphria (APH), Knight Therapeutics (KHTRF), Hydropothecary (THCX), OrganiGram (OGI), Supreme Cannabis (FIRE), Weed (BUDZ), OrganiGram (OGRMF), Medical Marijuana (MJNA), Benchmark (BMK) and MPX Bioceutical (MPX).
Who are MedReleaf's key executives?
MedReleaf's management team includes the folowing people:
- Mr. Neil J. Closner, CEO, Co-Founder & Director
- Mr. Igor Gimelshtein, CFO & Corp. Sec.
- Mr. Donald Courtney, Chief Operating Officer
- Mr. Umar Syed, Sr. VP of Corp. Devel.
- Mr. Angelo Fefekos, Vice-Pres of Clinical Affairs & Quality Compliance
Has MedReleaf been receiving favorable news coverage?
Media stories about LEAF stock have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. MedReleaf earned a media sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the company an impact score of 46.12 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of MedReleaf?
Shares of LEAF and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is MedReleaf's stock price today?
One share of LEAF stock can currently be purchased for approximately C$28.29.
How big of a company is MedReleaf?
MedReleaf has a market capitalization of C$1.91 billion.
MarketBeat Community Rating for MedReleaf (LEAF)
MarketBeat's community ratings are surveys of what our community members think about MedReleaf and other stocks. Vote "Outperform" if you believe LEAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LEAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
